WHO vaccine-preventable diseases: monitoring system. 2020 global summary
Last updated 15-July-2020 (data as of 12-October-2020)
Next overall update End 2020
 		EPI mother and child logo         
Select a country
Development status: Developed economy GNI / capita (US$): 9'4101 Infant (under 12 months) mortality rate: 62
GDP / capita (US$): 24'5611 Child (under 5 years) mortality rate: 82

Population data in thousands3
  2019  2018  2017  2016  2015  2000  1990  1980 
Total population 7'000  7'052  7'102  7'152  7'200  7'998  8'841  8'879 
Births 62  63  64  65  66  65  105  133 
Surviving infants 62  62  63  64  65  64  103  130 
Pop. less than 5 years 315  313  313  320  338  322  558  680 
Pop. less than 15 years 1'028  1'029  1'026  1'024  1'028  1'252  1'799  1'967 
Female 15-49 years 1'482  1'503  1'525  1'547  1'569  1'938  2'110  2'145 

Number of reported cases

(Click for retrospective incidence data for Bulgaria)
Diphtheria
ChartChart
  0  0  0  0  0  0  0  2 
Japanese encephalitis
  _  _  _  0  _  _  _  _ 
Measles***
ChartChart
  1'231  13  165  1  0  46  147  10'763 
Mumps
ChartChart
  50  27  15  19  18  2'357  _  _ 
Pertussis
ChartChart
  70  114  116  98  35  106  26  154 
Polio*
ChartChart
  0  0  0  0  0  0  0  15 
Rubella***
ChartChart
  0  1  0  2  5  28'449  _  _ 
Rubella (CRS)
ChartChart
  0  0  0  0  0  _  _  _ 
Tetanus (neonatal)
ChartChart
  0  _  _  0  0  0  0  0 
Tetanus (total)**
ChartChart
  _  _  _  4  0  3  7  18 
Yellow fever
  0  0  _  0  0  0  _  _ 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.
*** For 2019, if a country did not submit a joint reporting form, measles and rubella cases were sourced from data reported through the monthly surveillance data available from:
https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/

Percentage target population vaccinated by antigen

 Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5
  (Click for retrospective coverage estimates data for Bulgaria)
Vaccine year result method % card seen                                                
BCG          96  96  96  96  96  98  _  _ 
DTP1          96  95  96  94  93  95  _  _ 
DTP3          93  92  92  92  91  93  _  _ 
IPV1          96  95  96  94  93  _  _  _ 
HepB_BD          98  96  97  96  97  98  _  _ 
HepB3          93  85  92  91  92  94  _  _ 
Hib3          _  92  92  92  87  90  _  _ 
JapEnc          _  _  _  _  _  _  _  _ 
MCV1          39  93  94  92  92  89  _  _ 
MCV2          95  87  92  88  87  83  _  _ 
MenA          _  _  _  _  _  _  _  _ 
PCV1          94  92  95  94  95  _  _  _ 
PCV2          94  92  94  93  93  _  _  _ 
PCV3          93  89  91  90  90  _  _  _ 
Pol3          93  92  92  92  91  94  _  _ 
Rota1          88  36  _  _  _  _  _  _ 
RotaC          46  31  _  _  _  _  _  _ 
RCV1          95  93  94  92  92  _  _  _ 
TT2plus          _  _  _  _  _  _  _  _ 
PAB          _  _  _  _  _  _  _  _ 
VAD1          _  _  _  _  _  _  _  _ 
YFV          93  _  _  _  _  _  _  _ 
* indicates the country reported above 100% coverage.
  Next update: Mid July 2021

WHO-UNICEF estimates6
  (Click for full retrospective WHO-UNICEF coverage estimates data for Bulgaria)
BCG
ChartChart
  96  96  96  96  96  98  99  99 
DTP1
ChartChart
  94  94  96  94  93  95  99  98 
DTP3
ChartChart
  92  92  92  92  91  93  99  98 
HepB3
ChartChart
  85  85  92  91  92  94  _  _ 
HepB_BD
ChartChart
  96  96  97  96  97  98  _  _ 
Hib3
ChartChart
  92  92  92  92  87  _  _  _ 
IPV1
ChartChart
  94  94  96  94  93  _  _  _ 
MCV1
ChartChart
  93  93  94  92  92  89  99  98 
MCV2
ChartChart
  87  87  92  88  87  83  _  _ 
PCV3
ChartChart
  88  88  91  90  90  _  _  _ 
Pol3
ChartChart
  92  92  92  92  91  94  99  99 
RCV1
ChartChart
  93  93  94  92  92  89  _  _ 
RotaC
ChartChart
  31  31  _  _  _  _  _  _ 
Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.
Number of districts in the country 28  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected 		100 
   
/
|
|
\
Greater or equal to 90% 86
From 80 to 89% 11
From 50 to 79% 4
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage 		0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2019 or latest available)

 Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; 7 months; 7 years; Yes
DTaPHibHepBIPV 2, 3, 4 months; Yes
DTaPHibIPV 2, 3, 4, 16 months; Yes
DTaPIPV 6 years; Yes
HepB_Pediatric birth; 1, 6 months; Yes
HPV 12-13 years; +6 months; Yes females (aged 12-13 years in line with National program for primary prophylaxis of cervical cancer 2017-2020)
Influenza_Adult >=65 years; Yes and adults with chronic conditions, healthcare workers, residents living in long-term care facilities
Influenza_Pediatric Yes children with chronic conditions
MMR 13 months; 12 years; Yes
Pneumo_conj 2, 3, 4, 12 months; Yes
Rotavirus 6, 10-24/10-16, 20-32 weeks; Yes
Td 12, 17, 25, 35, 45, 55 years; Yes

Immunization indicators
Indicator Expected answer 2019  2018  2017  2016  2015  2014  2013 
Planning and management
Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
System performance
Total Nº districts in country number 28  28  28  28  28  28  28 
Nº districts with DTP3 coverage >=80% number 27  28  26  26  23  28  28 
% of districts with DTP3 coverage >=80% From 0 to 100% 96  100  93  93  82  100  100 
Nº districts with measles (MCV1) coverage >=95% number 10  15  12  9  14  16  13 
% of districts with MCV1 coverage >=95% From 0 to 100% 36  54  43  32  50  57  46 
Safety
Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Finance
% of Immunization expenditure financed, using Government funds? From 0 to 100%             100 
National Immunization Advisory Mechanism
Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  No  No 

Sources
 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.

Employment | Other UN Sites | Search | Suggestions | RSS | Privacy
© World Health Organization 2021. All rights reserved